Table 2.
The clinical outcomes of hypertensive patients with or without CCBs in COVID-19 patients.
| Clinical outcome | CCBs (n = 1078 for unmatched; n = 359 for matched) | Non-CCBs (n = 371 for unmatched; n = 359 for matched) | RR (95% CI) | Statistics (Z/χ2) | P value |
| Death, n (%) | |||||
| Unmatched | 25 (2.23) | 23 (6.20) | 0.36 (0.20–0.64) | 12.98∗ | 0.0003 |
| Matched | 7 (1.95) | 21 (5.85) | 0.32 (0.13–0.76) | 7.61∗ | 0.0058 |
| Transfer to ICU, n (%) | |||||
| Unmatched | 27 (2.50) | 15 (4.04) | 0.61 (0.32–1.16) | 2.32∗ | 0.1276 |
| Matched | 6 (1.67) | 14 (3.90) | 0.42 (0.16–1.10) | 3.38∗ | 0.0696 |
| Time after admission, days, median (IQR) | |||||
| Unmatched | 15 (10, 21) | 13 (8, 18) | NA | −6.21† | <0.0001 |
| Matched | 16 (10, 21) | 13 (8, 18) | NA | −4.59† | <0.0001 |
∗χ2-statistics; †Z-statistics. CCBs: Calcium channel blockers; CI: Confidence interval; ICU: Intensive care unit; IQR: Interquartile range; NA: Not applicable; RR: Risk ratio.